The aggregate market value of pharmaceutical industry increased more than 9 trillion won ($7.9 billion) at the stock exchange, or KOSPI market, while dwindling more than 4 trillion won in the KOSDAQ market, last year.
Currently, the Korea Exchange classifies the manufacturers of medical substances and medicinal products as “medicine industry” in the KOSPI market, and as “pharmaceutical industry” in the KOSDAQ market.
The aggregate market value of medicine industry accounts for 2 percent of the total of the KOSPI market, while that of the pharmaceutical industry accounts for 22 percent of the total KOSDAQ market.
As the result of comparing the aggregate market value from Aug. 16, 2016, and Aug. 14, 2017, the total market price of 12 industries dropped in 12 industries while rose in 13 sectors in the KOSPI market over the past year.
In the KOSDAQ market, the aggregate market prices of 14 industries have declined and those of nine sectors increased for one year.
The market value of “medicine industry” in the KOSPI market stands at 41.67 trillion won now, up 9.57 trillion won from the 32.10 trillion won a year ago.
During the same period, the market value of “pharmaceutical industry” in the KOSDAQ market fell 4.81 trillion won, from 40.82 trillion won to 36.01 trillion won. It was the second-steepest drop among 23 industries, following the decrease of the Internet industry with 6.17 trillion won.
In the tech-heavy KOSDAQ market, the top-three stocks regarding market value were drugmakers -- Celltrion셀트리온 with the market capitalization of 12.83 trillion won, followed by Celltrion Healthcare셀트리온헬스케어(6.65 trillion won), and Medytox메디톡스(2.97 trillion won).
Chasing them among pharmaceutical companies were No. 5 Hugel 휴젤 (2.2 trillion) No. 9 Viromed 바이로메드(1.6 trillion won) and No. 10 Sillaje신라젠(1.5 trillion won).
In the KOSPI market, LG Chem LG화학, in which life science business takes a relatively small share of sales, is placed at the 11th place with 24.24 trillion won, followed by No. 16 Samsung Biologics삼성바이오로직스 (17 trillion won) and No. 73 Hanmi Pharmaceutical한미약품(3.8 trillion won).
<© Korea Biomedical Review, All rights reserved.>